BioNexus Gene Lab vs EUDA Health
BGLC and EUDA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGLC and EUDA compare
EUDA Health grew revenue faster over the last twelve months (70.0% versus −67.3% for BioNexus Gene Lab).
EUDA Health keeps more of each dollar of sales as profit, with a net margin of −40.7% compared with −82.4% at BioNexus Gene Lab.
BioNexus Gene Lab scores higher on the StockData Score (8 against 5 for EUDA Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGLC | EUDA |
|---|---|---|
| Size and price | ||
| Market cap | $2.5M | – |
| Share price | $0.859 | $14.66 |
| Change, 1 year | −83.6% | −78.6% |
| Change, 5 years | −99.6% | – |
| Beta (5Y) | 0.87 | 0.33 |
| Employees | 6 | 123 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× | – |
| P/B | 0.3× | – |
| FCF yield | −33.9% | – |
| Fair value | $7.89 | – |
| Margin of safety | 89.1% | – |
| Growth | ||
| Revenue growth (TTM) | −67.3% | 70.0% (better) |
| Revenue growth, 5Y average | −8.2% | – |
| Profitability | ||
| Gross margin | 12.3% | 43.9% (better) |
| Operating margin | −81.8% | −36.3% (better) |
| Net margin | −82.4% | −40.7% (better) |
| FCF margin | −27.3% (better) | −36.7% |
| Return on equity | −33.7% (better) | −245% |
| Return on invested capital | −32.3% (better) | −227% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −10.8× |
| Current ratio | 6.08 (better) | 2.53 |
| Altman Z-score | 0.39 | – |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 0.49% | – |
| Held by insiders | 31.0% | 24.4% |
| Short interest, % of float | 0.16% | – |
Go deeper
- BGLC stock overview
- BGLC income statement
- BGLC valuation and score
- EUDA stock overview
- EUDA income statement
- EUDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.